United Therapeutics Corporation (UTHR)
Return on assets (ROA)
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | 1,195,100 | 1,110,900 | 1,069,400 | 1,050,500 | 984,800 | 899,800 | 871,500 | 728,300 | 727,300 | 707,400 | 630,800 | 687,400 | 475,800 | 462,400 | 470,900 | 405,400 | 514,800 | 468,600 | 429,800 | 527,800 |
Total assets | US$ in thousands | 7,364,000 | 7,123,100 | 6,723,200 | 6,495,200 | 7,167,000 | 7,023,600 | 6,681,300 | 6,346,000 | 6,044,500 | 5,781,600 | 5,543,300 | 5,359,800 | 5,169,100 | 5,048,900 | 4,844,900 | 4,641,000 | 4,615,000 | 4,411,200 | 4,219,400 | 4,025,900 |
ROA | 16.23% | 15.60% | 15.91% | 16.17% | 13.74% | 12.81% | 13.04% | 11.48% | 12.03% | 12.24% | 11.38% | 12.83% | 9.20% | 9.16% | 9.72% | 8.74% | 11.15% | 10.62% | 10.19% | 13.11% |
December 31, 2024 calculation
ROA = Net income (ttm) ÷ Total assets
= $1,195,100K ÷ $7,364,000K
= 16.23%
United Therapeutics Corporation's return on assets (ROA) has been fluctuating over the past few years. The ROA ranged from a low of 8.74% in March 2021 to a high of 16.23% in December 2024.
Overall, the ROA trend shows some volatility but generally demonstrates improvement towards the end of the period. This indicates that the company has been more effective in generating profits relative to its assets. It is important to continue monitoring the ROA to assess the company's efficiency in utilizing its assets to generate earnings for its shareholders.
Peer comparison
Dec 31, 2024
Company name
Symbol
ROA
United Therapeutics Corporation
UTHR
16.23%
Abbott Laboratories
ABT
16.46%
AbbVie Inc
ABBV
3.17%
ACADIA Pharmaceuticals Inc
ACAD
19.07%
Alkermes Plc
ALKS
17.86%
Amphastar P
AMPH
10.11%
ANI Pharmaceuticals Inc
ANIP
-1.44%
Arcus Biosciences Inc
RCUS
-24.61%
Biomarin Pharmaceutical Inc
BMRN
6.11%
Bristol-Myers Squibb Company
BMY
-9.66%
Catalyst Pharmaceuticals Inc
CPRX
15.19%